Effects of Artesunate prevent nephritis via the Toll‑like receptor 4/nuclear factor‑κB signaling pathway in rats

Wan,Rong  Jun; Li,Yue  Hong

doi:10.3892/mmr.2017.7362

Effects of Artesunate prevent nephritis via the Toll‑like receptor 4/nuclear factor‑κB signaling pathway in rats

Authors:
- Rong Jun Wan
- Yue Hong Li
View Affiliations

Affiliations: Department of Urology, Tianjin Nankai Hospital, Tianjin, Nankai 300100, P.R. China
Published online on: August 24, 2017 https://doi.org/10.3892/mmr.2017.7362
Pages: 6389-6395

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The active ingredient in Artemisia carvifolia, artemisinin, may alleviate inflammation and toxicity. Artemisinin and its derivatives are first‑line anti‑malarial drugs currently, which have rapid effects on fever caused by malaria parasites with fewer side effects. The present study investigated the effects of Artesunate in a mouse nephritis model. Mice were injected intraperitoneally with 500 µl pristine to induce nephritis, and were treated with 28.8 mg/kg Artesunate. Subsequently, proteinuria, renal function, and tumor necrosis factor (TNF)‑α and interleukin (IL)‑6 levels were assessed to evaluate the effects of Artesunate on nephritis. Western blot analysis was used to measure the protein expression levels of α‑smooth muscle actin (SMA), TLR4, myeloid differentiation primary response gene 88 (MyD88), NF‑κB p65 and transforming growth factor (TGF)‑β1 to investigate the underlying mechanisms of Artesunate on nephritis. The results demonstrated that Artesunate reduced proteinuria and preserved renal function in nephritis mice. Artesunate attenuated TNF‑α and IL‑6 levels, suppressed α‑SMA, TLR4, MyD88, NF‑κB p65 and TGF‑β1 protein expression, and decreased caspase‑3 activity in nephritis mice. These results indicated that the effects of Artesunate may prevent nephritis and inhibit inflammation via the TLR4/NF‑κB signaling pathway in mice. Therefore, Artesunate may be a potential therapeutic agent to prevent nephritis.

View Figures

View References

1	Rabrenović V, Poskurica M, Kovačević Z, Nešić V, Savin M, Mitić B, Dimković N, Čučković Č, Vujić D, Plješa S, et al: Treatment of lupus nephritis by mycophenolate mofetil. Kidney Blood Press Res. 33:297–303. 2010. View Article : Google Scholar : PubMed/NCBI
2	Wang J, Hu W, Xie H, Zhang H, Chen H, Zeng C, Liu Z and Li L: Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: Mycophenolate mofetil or intravenous cyclophosphamide. Lupus. 16:707–712. 2007. View Article : Google Scholar : PubMed/NCBI
3	Mok CC, Ying KY, Yim CW, Siu YP, Tong KH, To CH and Ng WL: Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: A randomised controlled trial and long-term follow-up. Ann Rheum Dis. 75:30–36. 2016. View Article : Google Scholar : PubMed/NCBI
4	Petersson L, Dexlin-Mellby L, Bengtsson AA, Sturfelt G, Borrebaeck CA and Wingren C: Multiplexing of miniaturized planar antibody arrays for serum protein profiling-a biomarker discovery in SLE nephritis. Lab Chip. 14:1931–1942. 2014. View Article : Google Scholar : PubMed/NCBI
5	Anders HJ, Banas B and Schlöndorff D: Signaling danger: Toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol. 15:854–867. 2004. View Article : Google Scholar : PubMed/NCBI
6	Ding Y, Liao W, He X, Xiang W and Lu Q: CSTMP exerts anti-inflammatory effects on LPS-induced human renal proximal tubular epithelial cells by inhibiting TLR4-mediated NF-κB pathways. Inflammation. 39:849–859. 2016. View Article : Google Scholar : PubMed/NCBI
7	Yang Z, Ding J, Yang C, Gao Y, Li X, Chen X, Peng Y, Fang J and Xiao S: Immunomodulatory and anti-inflammatory properties of artesunate in experimental colitis. Curr Med Chem. 19:4541–4551. 2012. View Article : Google Scholar : PubMed/NCBI
8	Luo Q, Lin J, Zhang L, Li H and Pan L: The anti-malaria drug artesunate inhibits cigarette smoke and ovalbumin concurrent exposure-induced airway inflammation and might reverse glucocorticoid insensitivity. Int Immunopharmacol. 29:235–245. 2015. View Article : Google Scholar : PubMed/NCBI
9	Lee IS, Ryu DK, Lim J, Cho S, Kang BY and Choi HJ: Artesunate activates Nrf2 pathway-driven anti-inflammatory potential through ERK signaling in microglial BV2 cells. Neurosci Lett. 509:17–21. 2012. View Article : Google Scholar : PubMed/NCBI
10	Bethell D, Se Y, Lon C, Tyner S, Saunders D, Sriwichai S, Darapiseth S, Teja-Isavadharm P, Khemawoot P, Schaecher K, et al: Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: A randomized clinical trial. PLoS One. 6:e192832011. View Article : Google Scholar : PubMed/NCBI
11	Saito T, Iwano M, Matsumoto K, Mitarai T, Yokoyama H, Yorioka N, Nishi S, Yoshimura A, Sato H, Ogahara S, et al: Significance of combined cyclosporine-prednisolone therapy and cyclosporine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome: A randomized controlled multicenter trial. Clin Exp Nephrol. 18:784–794. 2014. View Article : Google Scholar : PubMed/NCBI
12	Kopp JB, Winkler CA, Zhao X, Radeva MK, Gassman JJ, D'Agati VD, Nast CC, Wei C, Reiser J, Guay-Woodford LM, et al: Clinical features and histology of apolipoprotein L1-associated nephropathy in the FSGS clinical trial. J Am Soc Nephrol. 26:1443–1448. 2015. View Article : Google Scholar : PubMed/NCBI
13	Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z, Chen J, Lin H, Liu F, He Y, et al: Multitarget therapy for induction treatment of lupus nephritis: A randomized trial. Ann Intern Med. 162:18–26. 2015. View Article : Google Scholar : PubMed/NCBI
14	Zhang L, Han C, Sun C, Meng H, Ye F, Na S, Chen F, Zhang D and Jin X: Serum levels of alpha-smooth muscle actin and c-Met as biomarkers of the degree of severity of Henoch-Schonlein purpura nephritis. Transl Res. 161:26–36. 2013. View Article : Google Scholar : PubMed/NCBI
15	Kawasaki Y, Suzuki J, Sakai N, Tanji M and Suzuki H: Predicting the prognosis of renal dysfunction by renal expression of alpha-smooth muscle actin in children with MPGN type 1. Am J Kidney Dis. 42:1131–1138. 2003. View Article : Google Scholar : PubMed/NCBI
16	Liu CY: Wakayama Symposium: Notch-FoxL2-α-SMA axis in eyelid levator muscle development and congenital blepharophimosis. Ocul Surf. 10:221–223. 2012. View Article : Google Scholar : PubMed/NCBI
17	Xu Y, Liu W, Fang B, Gao S and Yan J: Artesunate ameliorates hepatic fibrosis induced by bovine serum albumin in rats through regulating matrix metalloproteinases. Eur J Pharmacol. 744:1–9. 2014. View Article : Google Scholar : PubMed/NCBI
18	Qiu S, Sun G, Zhang Y, Li X and Wang R: Involvement of the NF-κB signaling pathway in the renoprotective effects of isorhamnetin in a type 2 diabetic rat model. Biomed Rep. 4:628–634. 2016. View Article : Google Scholar : PubMed/NCBI
19	Hong F, Wu N, Ge Y, Zhou Y, Shen T, Qiang Q, Zhang Q, Chen M, Wang Y, Wang L and Hong J: Nanosized titanium dioxide resulted in the activation of TGF-β/Smads/p38MAPK pathway in renal inflammation and fibration of mice. J Biomed Mater Res A. 104:1452–1461. 2016. View Article : Google Scholar : PubMed/NCBI
20	Susianti H, Iriane VM, Dharmanata S, Handono K, Widijanti A, Gunawan A and Kalim H: Analysis of urinary TGF-β1, MCP-1, NGAL, and IL-17 as biomarkers for lupus nephritis. Pathophysiology. 22:65–71. 2015. View Article : Google Scholar : PubMed/NCBI
21	Yang W, Wang J, Shi L, Yu L, Qian Y, Liu Y, Wang W and Cheng S: Podocyte injury and overexpression of vascular endothelial growth factor and transforming growth factor-beta 1 in adriamycin-induced nephropathy in rats. Cytokine. 59:370–376. 2012. View Article : Google Scholar : PubMed/NCBI
22	Capuano A, Costanzi S, Peluso G, Zannoni G, Vellone VG, Gremese E, Zoli A, Scott C, Beltrami CA, Romano G and Ferraccioli G: Hepatocyte growth factor and transforming growth factor beta1 ratio at baseline can predict early response to cyclophosphamide in systemic lupus erythematosus nephritis. Arthritis Rheum. 54:3633–3639. 2006. View Article : Google Scholar : PubMed/NCBI
23	Jiang L, Zhang Y, Sun Y, Hu L and Gao D: Artesunate attenuates lung injury in paraquat-intoxicated rats via downregulation of inflammatory cytokines. Clin Lab. 61:1601–1607. 2015. View Article : Google Scholar : PubMed/NCBI
24	Chassin C, Goujon JM, Darche S, du Merle L, Bens M, Cluzeaud F, Werts C, Ogier-Denis E, Le Bouguénec C, Buzoni-Gatel D and Vandewalle A: Renal collecting duct epithelial cells react to pyelonephritis-associated Escherichia coli by activating distinct TLR4-dependent and -independent inflammatory pathways. J Immunol. 177:4773–4784. 2006. View Article : Google Scholar : PubMed/NCBI
25	Ding Y, Yang H, Xiang W, He X, Liao W and Yi Z: CD200R1 agonist attenuates LPS-induced inflammatory response in human renal proximal tubular epithelial cells by regulating TLR4-MyD88-TAK1-mediated NF-κB and MAPK pathway. Biochem Biophys Res Commun. 460:287–294. 2015. View Article : Google Scholar : PubMed/NCBI
26	Correa-Costa M, Braga TT, Semedo P, Hayashida CY, Bechara LR, Elias RM, Barreto CR, Silva-Cunha C, Hyane MI, Gonçalves GM, et al: Pivotal role of Toll-like receptors 2 and 4, its adaptor molecule MyD88, and inflammasome complex in experimental tubule-interstitial nephritis. PLoS One. 6:e290042011. View Article : Google Scholar : PubMed/NCBI
27	Wang D, Shi J, Lv S, Xu W, Li J, Ge W, Xiao C, Geng D and Liu Y: Artesunate attenuates lipopolysaccharide-stimulated proinflammatory responses by suppressing TLR4, MyD88 expression, and NF-κB activation in microglial cells. Inflammation. 38:1925–1932. 2015. View Article : Google Scholar : PubMed/NCBI